Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial
AuthorHaac, Bryce E
O'Hara, Nathan N
Manson, Theodore T
Slobogean, Gerard P
Castillo, Renan C
O'Toole, Robert V
Stein, Deborah M
PublisherPublic Library of Science
MetadataShow full item record
AbstractBACKGROUND: Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications. We used a patient-centered weighted composite outcome to globally evaluate aspirin versus low-molecular-weight heparin (LMWH) for VTE prevention in fracture patients. METHODS: We conducted an open-label randomized clinical trial of adult patients admitted to an academic trauma center with an operative extremity fracture, or a pelvis or acetabular fracture. Patients were randomized to receive LMWH (enoxaparin 30-mg) twice daily (n = 164) or aspirin 81-mg twice daily (n = 165). The primary outcome was a composite endpoint of bleeding complications, deep surgical site infection, deep vein thrombosis, pulmonary embolism, and death within 90 days of injury. A Global Rank test and weighted time to event analysis were used to determine the probability of treatment superiority for LMWH, given a 9% patient preference margin for oral administration over skin injections. RESULTS: Overall, 18 different combinations of outcomes were experienced by patients in the study. Ninety-nine patients in the aspirin group (59.9%) and 98 patients in the LMWH group (59.4%) were event-free within 90 days of injury. Using a Global Rank test, the LMWH had a 50.4% (95% CI, 47.7-53.2%, p = 0.73) probability of treatment superiority over aspirin. In the time to event analysis, LMWH had a 60.5% probability of treatment superiority over aspirin with considerable uncertainty (95% CI, 24.3-88.0%, p = 0.59). CONCLUSION: The findings of the Global Rank test suggest no evidence of superiority between LMWH or aspirin for VTE prevention in fracture patients. LMWH demonstrated a 60.5% VTE prevention benefit in the weighted time to event analysis. However, this difference did not reach statistical significance and was similar to the elicited patient preferences for aspirin.
Heparin, Low-Molecular-Weight--therapeutic use
Venous Thromboembolism--prevention & control
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/13542
- Post-discharge adherence with venous thromboembolism prophylaxis after orthopedic trauma: Results from a randomized controlled trial of aspirin versus low molecular weight heparin.
- Authors: Haac BE, Van Besien R, O'Hara NN, Slobogean GP, Manson TT, O'Toole RV, Johal H, Berger PZ, Reahl GB, Marinos D, Degani Y, Mascarenhas D, Connelly D, Scalea TM, Stein DM
- Issue date: 2018 Apr
- Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome.
- Authors: Yi X, Lin J, Wang C, Zhang B, Chi W
- Issue date: 2014 Jul
- Mobile Compression Reduces Bleeding-related Readmissions and Wound Complications After THA and TKA.
- Authors: Arsoy D, Giori NJ, Woolson ST
- Issue date: 2018 Feb
- Safety and effectiveness of aspirin and enoxaparin for venous thromboembolism prophylaxis after total hip and knee arthroplasty: a systematic review.
- Authors: Nadi S, Vreugdenburg TD, Atukorale Y, Ma N, Maddern G, Rovers M
- Issue date: 2019 Oct
- Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
- Authors: Marietta M, Vandelli P, Mighali P, Vicini R, Coluccio V, D'Amico R, COVID-19 HD Study Group.
- Issue date: 2020 Jun 26